Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia
Journal
Clinical Infectious Diseases
Journal Volume
52
Journal Issue
3
Pages
352-360
Date Issued
2011
Author(s)
Abstract
Background: Acinetobacter baumannii complex infections are increasing in prevalence and are associated with a high mortality. Biochemical classification tests cannot differentiate A. baumannii (genospecies 2) from other genospecies. Genospecies typing offers a potential tool to determine whether there are major differences in pathogenicity among the genospecies. Methods: Adult patients with A. baumannii complex bacteremia in intensive care units were prospectively observed from January 2007 through July 2009. A. baumannii complex was identified by biochemical methods and the Phoenix bacterial identification system. Genospecies were identified by 16S-23S ribosomal RNA intergenicspacer sequencing. Results: Among the 135 patients with A. baumannii complex bacteremia, 87 (64.4%) had isolates that belonged to genospecies 2, 36 (26.7%) had isolates that belonged to genospecies 13TU, and 12 (8.9%) had isolates that belonged to genospecies 3. Patients with A. baumannii (genospecies 2) bacteremia were more likely to have pneumonia than were patients with bacteremia due to genospecies 13TU (63.2 % vs 27.8%; P 5.001), whereas patients with bacteremia due to genospecies 13TU were more likely to have primary bacteremia (69.4% vs 20.7%; P <.001). Genospecies 2 was less susceptible to antibiotics than were other genospecies. It was associated with a higher rate of mortality than was genospecies 13TU (58.6% vs 16.7%; P <.001). On multivariate analysis, genospecies 2 was an independent predictor of mortality (odds ratio, 5.46; 95% confidence interval, 2.00-14.91; P =.001). Conclusions: Genospecies 2 of the A. baumannii complex was associated with greater resistance to antibiotics and higher mortality among bacteremic patients, compared with other genospecies, especially genospecies 13TU. These findings emphasize the need to focus on genospecies to better understand the pathogenesis and epidemiology of infections caused by the A. baumannii complex. ? The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.
SDGs
Other Subjects
amikacin; aztreonam; beta lactam antibiotic; carbapenem; cefepime; ceftazidime; ciprofloxacin; colistin; gentamicin; levofloxacin; meropenem; quinoline derived antiinfective agent; RNA 16S; RNA 23S; spacer DNA; sultamicillin; tigecycline; timentin; Acinetobacter baumannii; Acinetobacter infection; adult; aged; antibiotic resistance; antibiotic sensitivity; antibiotic therapy; article; bacteremia; bacterial strain; bacterium identification; bacterium isolate; controlled study; DNA sequence; female; human; intensive care unit; major clinical study; male; mortality; pneumonia; priority journal; prospective study; species identification; strain difference; Acinetobacter baumannii; Acinetobacter Infections; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacterial Typing Techniques; Cluster Analysis; DNA, Bacterial; DNA, Ribosomal Spacer; Drug Resistance, Bacterial; Genotype; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Typing; Phylogeny; Prospective Studies; Sequence Analysis, DNA; Treatment Outcome
Type
journal article